BENZOIC ACID, 4-((4-AMINO-3-(4-CYCLOHEXYL-1-PIPERAZINYL)-9,10-DIHYDRO-9,10-DIOXO-1-ANTHRACENYL)AMINO)-
Head and Neck Cancers - Salivary Gland
VM Oncology, LLCSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Head and Neck Cancers - Salivary Gland cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TRASTUZUMAB Genentech, Inc. | Phase 2 | BB |
Carboplatin European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 | BB |
Cetuximab Fox Chase Cancer Center | Phase 1/2 | B |
Irinotecan AIDS Malignancy Consortium | Phase 1/2 | B |
Pembrolizumab OncoC4, Inc. | Phase 2 | B |
View all 42 →
Same molecule, other indications
BENZOIC ACID, 4-((4-AMINO-3-(4-CYCLOHEXYL-1-PIPERAZINYL)-9,10-DIHYDRO-9,10-DIOXO-1-ANTHRACENYL)AMINO)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →